A scientific statement has been published by the American College of Cardiology regarding inflammation and cardiovascular disease.

There’s a need in secondary prevention for personalized risk estimates to motivate patients and guide care, researchers say.

Combining an antiplatelet with oral anticoagulants in stroke patients with AF and cardiovascular disease slightly lowers ...

Despite advancements in treatment and prevention, patients with established atherosclerotic cardiovascular disease (ASCVD) ...

An expert discusses the growing burden of atherosclerotic cardiovascular disease (ASCVD) in the U.S., emphasizing the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s ...

Cardiovascular disease remains one of the dominant non-communicable causes of death in India, contributing substantially to ...

Despite advancements in treatment and HIV viral suppression, people with HIV experience a risk of myocardial infarction that is 1.73 times higher than in people without HIV.[1][1] Believed to be in ...

– Co-founded by industry leaders John Maraganore, Ph.D., and Clive Meanwell, M.D., pioneers in RNAi and cardiovascular innovation – – Developing Klotho Health, a proprietary AI-enabled tool to predict ...

In patients with ASCVD who receive dialysis, statins decrease risk for MACE and all-cause mortality. Statins are associated with a decrease in all-cause mortality and major adverse cardiovascular ...

The panel favored statins for patients with a 10-year ASCVD risk score below 5%, but recommended patient-clinician risk discussions that accounted for additional HIV-related risk factors that could ...

Tourmaline Bio’s lead candidate sparkled in a mid-stage data drop, prepping the biotech to develop the former Pfizer asset further in a pair of cardiovascular indications. Pacibekitug, an antibody ...